ArticleChemMedChem2026
Sultams as Dual Inhibitors of Human Carbonic Anhydrase and Thioredoxin Reductase.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cancer remains a leading cause of mortality, often complicated by drug resistance arising from single-target therapies. Dual inhibitors that simultaneously target multiple cancer-related defense mechanisms offer a promising strategy to overcome these limitations. Herein, we report the design, synthesis, and biological evaluation of a series of sultam-based N-acyl derivatives (8a-k and 9a-k) as potential dual inhibitors of thioredoxin reductase (TrxR1) and tumor-associated carbonic anhydrases (CA IX and XII). TrxR1 screening identified a few active compounds, with inhibitory potency strongly influenced by the type and orientation of substituents. CA inhibition assays revealed pronounced selectivity for CA IX/XII, while off-target isoforms CA I and CA II remained unaffected. These findings highlight the potential of sultam derivatives as dual-targeting anticancer agents and provide a foundation for further optimization toward selective, multi-pathway cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.